12 Best Growth Stocks Under $25 to Buy Now

Page 9 of 11

3. Wave Life Sciences Ltd. (NASDAQ:WVE)

Number of Hedge Fund Holders: 34

Share Price as of January 8, 2024: $13.08

Wave Life Sciences Ltd. (NASDAQ:WVE) is a biotechnology company that develops drugs to treat genetic diseases, conventionally deemed as untreatable. The company’s prowess lies in its innovative approach which leverages RNA-targeting modalities to treat disorders. Over the past few months, the company has delivered solid performance by accelerating trials and expanding its drug portfolio.

As a result, the company posted solid financial results in the third quarter of 2024, with revenue worth $7.7 million. While the company saw a decline in revenue from the third quarter of 2023, WVE expects that this will not impact its future progress and suggests that its performance is in line with its goals. Research and development costs during the same period were recorded at $41.2 million, up from $31.6 million in the same quarter of 2023.

Investors are bullish on the stock because of incoming positive data from trials, which also led the stock to gain value. Its preliminary data has proven to be quite promising, fueling shared optimism among investors and analysts despite weak financials.

Page 9 of 11